Indusatumab vedotin: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary Tag: Manual revert |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 26: | Line 26: | ||
[[Category:Cancer treatment]] | [[Category:Cancer treatment]] | ||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
{{No image}} | |||
Latest revision as of 12:52, 18 March 2025
Indusatumab vedotin is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Seattle Genetics.
Mechanism of Action[edit]
Indusatumab vedotin is an antibody-drug conjugate (ADC) that combines an antibody specific for tissue factor (TF), a protein that plays a role in tumor growth and progression, with a potent cell-killing agent. The antibody portion of the ADC binds to TF on the surface of cancer cells, delivering the cell-killing agent directly to the cells.
Clinical Trials[edit]
Indusatumab vedotin has been evaluated in several clinical trials for the treatment of various types of cancer. These trials have shown promising results, with some patients experiencing significant reductions in tumor size.
Side Effects[edit]
Like all drugs, indusatumab vedotin can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and decreased appetite. More serious side effects can include nerve damage and low blood cell counts.
See Also[edit]
References[edit]
<references />
